MTOR and neoplasm: Nonetheless, regardless of the specific resistance mechanism, our results clearly show that the patient-derived tumor cells are ‘oncogene addicted’ to PI3K/mTOR activation and therefore inhibition of this pathway is sufficient to overcome cetuximab resistance in this patient.